Journal of Multiple Sclerosis

Biography

Dr. Svetlana Khaiboullina received her Ph.D. in Pharmacology from the University of Chelyabinsk Medical Institute, Russia. Her Post-Doctoral training includes Cell and Molecular Biology program, University of Nevada, Reno. Currently, she is working as a Research Assistant professor, University of Nevada, Reno. Her research is focused on understanding the pathogenesis of multiple sclerosis and other immune aberrant conditions. Specifically, she is interested in unraveling the role of the immune mediators in leukocyte activation, trafficking and tissue targeting in multiple sclerosis. Cytokines are immune mediators released by leukocytes as well as tissue cells upon detection of the damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). Studies have shown that cytokines could be involved in the onset and the progression of the disease. This prompted her to initiate the multi-omics investigation aimed to determine the key cytokines and other omics that could identify the biomarkers for diagnosis and treatment of multiple sclerosis. She is honored as a Fulbright Specialist (Infectious Diseases and Virology, Grant Award) 2014 – present and • Invited lecturer to the Fellowship in Integrative Cancer Therapies (Cancer Module II, 2013). She is also serving as a potential reviewer for the Journal of General Virology, Frontiers in Immunology and Frontiers Microbiology and Peer-Reviewed Medical Research Program grant study section.

Research Interest

Her research is focused on understanding the pathogenesis of multiple sclerosis and other immune aberrant conditions. Specifically, she is interested in unraveling the role of the immune mediators in leukocyte activation, trafficking and tissue targeting in multiple sclerosis. Cytokines are immune mediators released by leukocytes as well as tissue cells upon detection of the damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). Studies have shown that cytokines could be involved in the onset and the progression of the disease. This prompted her to initiate the multi-omics investigation aimed to determine the key cytokines and other omics that could identify the biomarkers for diagnosis and treatment of multiple sclerosis.